Evidence map›Paper›PMID 42512373›Full record

ReviewCancers2026

Current Molecular-Targeted Therapies in Melanoma and Their Mechanism of Resistance.

Rose Bahari, Molly Nguyen, Nayyab Sohail, Stephanie Lopez, Subaranjana Saravanaguru Vasanthi, Jeeya Amin, Dhruv Ramaswami, Georgia Kapetaneas, Riya Karne, Usama Altayeh and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rose BahariDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0001-0397-7779
Molly NguyenDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0000-7093-0500
Nayyab SohailDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.
Stephanie LopezDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0000-2062-0854
Subaranjana Saravanaguru VasanthiDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0009-3548-247X
Jeeya AminDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0009-4795-1659
Dhruv RamaswamiDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0000-0002-9798-2877
Georgia KapetaneasDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0002-4664-4576
Riya KarneDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0000-5871-686X
Usama AltayehDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.
Kathryn Joi RodgersDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.
Aneri Prashant MehtaDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0009-0001-8414-2211
Neelu PuriDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USA.ORCID 0000-0001-6973-5361

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is an aggressive skin cancer that has the potential to metastasize to the lymph nodes, lungs, liver, and brain. Therefore, the prevention and treatment of this condition are essential for achieving lower incidence rates and improving patient outcomes. Traditional treatment methods like surgery, radiation therapy, and chemotherapy have shown limited efficacy in the treatment of metastatic melanoma, and hence new treatment strategies have been developed. These recently developed treatment options include combining targeted therapies with immunotherapies to reduce drug resistance and improve overall effectiveness in preventing melanoma progression. Moreover,

Indexed as

BRAF mutationsclinical trialscombination therapycutaneous melanomadrug resistanceimmune checkpoint inhibitorsimmunotherapyMAPK/ERK signalingMEK inhibitionmelanomaNRAS mutationsRAS signalingtargeted therapytherapeutic resistance

Identifiers

PMID42512373
PMCPMC13407313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.